Form 4: Kezar Life Sciences Director Granted Stock Options Under 10b5-1 Plan

Kezar Life Sciences, Inc. Director Elizabeth Garner was granted 5,000 stock options with an exercise price of $4.46, vesting fully on June 18, 2026, as part of a pre-arranged Rule 10b5-1 plan.

Summary

• Elizabeth Garner, a Director at Kezar Life Sciences, Inc. (KZR), acquired 5,000 stock options.
• The stock options have an exercise price of $4.46 per share.
• The grant date for these options was June 18, 2025.
• One-hundred percent (100%) of the shares subject to the option will vest on June 18, 2026, contingent on Ms. Garner's continued service through that date.
• The options are exercisable until their expiration date of June 17, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. This is a routine compensation event that aligns director interests with shareholders, but it does not provide new operational or financial performance information.

Positives

• The grant of stock options to a director aligns the director's financial interests with the long-term performance and shareholder value of Kezar Life Sciences, Inc.
• The use of a Rule 10b5-1 plan for this transaction indicates a pre-arranged trading plan, which helps mitigate concerns about insider trading based on material non-public information.

Risks

• The value of the stock options is directly dependent on the future stock price of Kezar Life Sciences, Inc.; if the stock price does not exceed the exercise price of $4.46, the options may expire worthless.
• The vesting of the options is subject to the reporting person continuing to provide service through the vesting date (June 18, 2026), meaning the options could be forfeited if service ceases before this date.

Future Outlook

This document, an SEC Form 4, details an insider transaction and does not provide any forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

Stock option grants are a standard component of executive and director compensation packages across various industries, including the biotechnology and life sciences sector. This practice is designed to attract and retain key talent while aligning their financial incentives with the long-term interests of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common form of equity compensation in the life sciences industry, consistent with global benchmarks for executive and board remuneration.
• The specific terms of the grant, such as the exercise price and vesting schedule, would typically be evaluated against Kezar Life Sciences' peer group compensation policies, though specific comparable companies or projects are not detailed in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's financial interests with the company's stock performance, potentially benefiting shareholders if the stock price increases over time.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The granted stock options will vest on June 18, 2026, provided Elizabeth Garner continues to provide service to the company.
• Following vesting, the options can be exercised at any time until their expiration on June 17, 2035.

Key Dates

Recommendation

Keywords

Kezar Life Sciences, KZR, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Compensation, Rule 10b5-1, Vesting